Human papillomavirus genotype-specific risks for cervical intraepithelial lesions
Prevalence of different HPV genotypes is changing after HPV vaccination. The associated risks are needed for optimizing cervical cancer screening. To estimate HPV type-specific prevalence, odds ratio (OR), and positive predictive value (PPV) for cervical cytological abnormalities, we determined 41 d...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-04-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1814097 |
| _version_ | 1797677259101831168 |
|---|---|
| author | Mari Nygård Bo T. Hansen Susanne K. Kjaer Maria Hortlund Laufey Tryggvadóttir Christian Munk Camilla Lagheden Lara G. Sigurdardottir Suzanne Campbell Kai-Li Liaw Joakim Dillner |
| author_facet | Mari Nygård Bo T. Hansen Susanne K. Kjaer Maria Hortlund Laufey Tryggvadóttir Christian Munk Camilla Lagheden Lara G. Sigurdardottir Suzanne Campbell Kai-Li Liaw Joakim Dillner |
| author_sort | Mari Nygård |
| collection | DOAJ |
| description | Prevalence of different HPV genotypes is changing after HPV vaccination. The associated risks are needed for optimizing cervical cancer screening. To estimate HPV type-specific prevalence, odds ratio (OR), and positive predictive value (PPV) for cervical cytological abnormalities, we determined 41 different HPV genotypes in cervical samples from a population-based sample of 8351 women aged 18–51 years before HPV vaccination era (V501-033; NCT01077856). Prevalence of HPV16 was 4.9% (95% CI: 4.4–5.5) with the PPV for high-grade cytology 11.2%, and OR 11.9 (95% CI: 8.5–16.5). Carcinogenic HPVs included in the nonavalent vaccine (HPV16,18,31,33,45,52,58) had a population prevalence of 14.4% (95% CI: 13.5–15.4), with PPV of 8.0% (95% CI: 6.8–9.3) and OR 23.7 (95% CI: 16.0–63.5) for high-grade cytology. HPV types currently included in most screening tests, but not vaccinated against (HPV35,39,51,56,59,66,68) had a joint prevalence of 8.5% (95% CI: 7.8–9.2) with PPV of 4.4% (95% CI: 3.3–5.7) and OR of 2.9 (95% CI: 2.0–4.0) for high-grade cytology. The other 27 non-carcinogenic genotypes had a prevalence of 11.8%, PPV of 2.9% (95% CI:2.1–3.9), and OR 1.5 (95% CI: 1.1–2.2.) for high-grade cytology. These results suggest that HPV screening tests in the post-vaccination era might perform better if restricted to the HPV types in the nonavalent vaccine and screening for all 14 HPV types might result in suboptimal balance of harms and benefits. |
| first_indexed | 2024-03-11T22:42:26Z |
| format | Article |
| id | doaj.art-1a3132436787418e979345f5da26171f |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:42:26Z |
| publishDate | 2021-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-1a3132436787418e979345f5da26171f2023-09-22T08:51:51ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-04-0117497298110.1080/21645515.2020.18140971814097Human papillomavirus genotype-specific risks for cervical intraepithelial lesionsMari Nygård0Bo T. Hansen1Susanne K. Kjaer2Maria Hortlund3Laufey Tryggvadóttir4Christian Munk5Camilla Lagheden6Lara G. Sigurdardottir7Suzanne Campbell8Kai-Li Liaw9Joakim Dillner10Cancer Registry of NorwayCancer Registry of NorwayDanish Cancer Society Research CenterSkåne University HospitalIcelandic Cancer SocietyDanish Cancer Society Research CenterSkåne University HospitalIcelandic Cancer SocietyCancer Registry of NorwayMerck Sharp & DohmeSkåne University HospitalPrevalence of different HPV genotypes is changing after HPV vaccination. The associated risks are needed for optimizing cervical cancer screening. To estimate HPV type-specific prevalence, odds ratio (OR), and positive predictive value (PPV) for cervical cytological abnormalities, we determined 41 different HPV genotypes in cervical samples from a population-based sample of 8351 women aged 18–51 years before HPV vaccination era (V501-033; NCT01077856). Prevalence of HPV16 was 4.9% (95% CI: 4.4–5.5) with the PPV for high-grade cytology 11.2%, and OR 11.9 (95% CI: 8.5–16.5). Carcinogenic HPVs included in the nonavalent vaccine (HPV16,18,31,33,45,52,58) had a population prevalence of 14.4% (95% CI: 13.5–15.4), with PPV of 8.0% (95% CI: 6.8–9.3) and OR 23.7 (95% CI: 16.0–63.5) for high-grade cytology. HPV types currently included in most screening tests, but not vaccinated against (HPV35,39,51,56,59,66,68) had a joint prevalence of 8.5% (95% CI: 7.8–9.2) with PPV of 4.4% (95% CI: 3.3–5.7) and OR of 2.9 (95% CI: 2.0–4.0) for high-grade cytology. The other 27 non-carcinogenic genotypes had a prevalence of 11.8%, PPV of 2.9% (95% CI:2.1–3.9), and OR 1.5 (95% CI: 1.1–2.2.) for high-grade cytology. These results suggest that HPV screening tests in the post-vaccination era might perform better if restricted to the HPV types in the nonavalent vaccine and screening for all 14 HPV types might result in suboptimal balance of harms and benefits.http://dx.doi.org/10.1080/21645515.2020.1814097denmarkhigh-risk hpvicelandliquid-based cytologylow-risk hpvnorwaypopulation-based prevalencesweden |
| spellingShingle | Mari Nygård Bo T. Hansen Susanne K. Kjaer Maria Hortlund Laufey Tryggvadóttir Christian Munk Camilla Lagheden Lara G. Sigurdardottir Suzanne Campbell Kai-Li Liaw Joakim Dillner Human papillomavirus genotype-specific risks for cervical intraepithelial lesions Human Vaccines & Immunotherapeutics denmark high-risk hpv iceland liquid-based cytology low-risk hpv norway population-based prevalence sweden |
| title | Human papillomavirus genotype-specific risks for cervical intraepithelial lesions |
| title_full | Human papillomavirus genotype-specific risks for cervical intraepithelial lesions |
| title_fullStr | Human papillomavirus genotype-specific risks for cervical intraepithelial lesions |
| title_full_unstemmed | Human papillomavirus genotype-specific risks for cervical intraepithelial lesions |
| title_short | Human papillomavirus genotype-specific risks for cervical intraepithelial lesions |
| title_sort | human papillomavirus genotype specific risks for cervical intraepithelial lesions |
| topic | denmark high-risk hpv iceland liquid-based cytology low-risk hpv norway population-based prevalence sweden |
| url | http://dx.doi.org/10.1080/21645515.2020.1814097 |
| work_keys_str_mv | AT marinygard humanpapillomavirusgenotypespecificrisksforcervicalintraepitheliallesions AT bothansen humanpapillomavirusgenotypespecificrisksforcervicalintraepitheliallesions AT susannekkjaer humanpapillomavirusgenotypespecificrisksforcervicalintraepitheliallesions AT mariahortlund humanpapillomavirusgenotypespecificrisksforcervicalintraepitheliallesions AT laufeytryggvadottir humanpapillomavirusgenotypespecificrisksforcervicalintraepitheliallesions AT christianmunk humanpapillomavirusgenotypespecificrisksforcervicalintraepitheliallesions AT camillalagheden humanpapillomavirusgenotypespecificrisksforcervicalintraepitheliallesions AT laragsigurdardottir humanpapillomavirusgenotypespecificrisksforcervicalintraepitheliallesions AT suzannecampbell humanpapillomavirusgenotypespecificrisksforcervicalintraepitheliallesions AT kaililiaw humanpapillomavirusgenotypespecificrisksforcervicalintraepitheliallesions AT joakimdillner humanpapillomavirusgenotypespecificrisksforcervicalintraepitheliallesions |